Drug intelligence / Profile preview

BMS-986277

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

BMS-986277 is an investigational antibody therapy developed by Bristol Myers Squibb for the treatment of epithelial cancers, specifically advanced epithelial tumors. It was studied as both a monotherapy and in combination with nivolumab (a PD-1 inhibitor) in clinical trials. The drug reached Phase 1/2 clinical development but the program was ultimately terminated and discontinued. The precise mechanism of action for BMS-986277 has not been disclosed or remains unknown, though it is described as an immunotherapy agent and may have involved immune modulation targeting solid tumors[1][2][3][4][5].

Beyond the preview

Go deeper on BMS-986277.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986277.

Explore the full profile